Skip Navigation

Treatment of Relapsed Chronic Myelogenous Leukemia

For information about the treatments listed below, see the Treatment Option Overview section.

In relapsed CML, the number of blast cells increases after a remission. Treatment of relapsed chronic myelogenous leukemia may include the following:

  • Targeted therapy with a tyrosine kinase inhibitor (dasatinib, nilotinib, bosutinib, asciminib, or higher doses of imatinib mesylate).
  • Donor stem cell transplant.
  • Chemotherapy.
  • Donor lymphocyte infusion.
  • Immunotherapy (interferon).
  • A clinical trial of new types or higher doses of targeted therapy or donor stem cell transplant.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

This information is not intended to replace the advice of a doctor. Navigating Care disclaims any liability for the decisions you make based on this information. This information was sourced and adapted from Adapted from the National Cancer Institute's Physician Data Query (PDQ®) Cancer Information Summaries on www.cancer.gov.